Targeting Astrocytic Connexin 43 Mitigates Glutamate-Driven Motor Neuron Stress in Late-Onset Spinal Muscular Atrophy

Area of Science:

• Neuroscience
• Genetics
• Cell Biology

Background:

• Spinal Muscular Atrophy (SMA) is caused by SMN1 gene mutations, leading to motor neuron degeneration.
• Astrocytes play a key role in regulating glutamate and mitigating motor neuron toxicity in SMA.
• Connexin 43 (Cx43) mediated astrocytic gap junctions are implicated in SMA pathology.

Purpose of the Study:

• Investigate the role of astrocytic connexin 43 (Cx43) in late-onset Spinal Muscular Atrophy (SMA).
• Analyze Cx43 expression, localization, and functional consequences in SMA models.
• Determine if Cx43 inhibition can reduce motor neuron toxicity.

Main Methods:

• Utilized a late-onset SMA mouse model, human-derived astrocytes, and murine astrocyte cultures.
• Assessed Cx43 expression via immunostaining, Western blotting, and qPCR.
• Evaluated functional consequences using ex vivo spinal cord slice cultures, Ca2+ imaging, and glutamate release assays.
• Administered pharmacological Cx43 inhibition using Gap27.

Main Results:

• Found significant Cx43 upregulation in SMA models and SMN-deficient astrocytes.
• Observed correlation between increased Cx43, elevated astrocytic glutamate release, and motor neuron toxicity.
• Demonstrated Cx43-dependent mechanisms for enhanced glutamate release via Ca2+ imaging.
• Showed that Gap27 reduced glutamate release and motor neuron Ca2+ responses.

Conclusions:

• Astrocytic Cx43 contributes to glutamate-mediated motor neuron toxicity in late-onset SMA.
• Highlights the importance of non-neuronal mechanisms in SMA pathogenesis.
• Suggests Cx43 as a potential therapeutic target for SMA.